Pregabalin In Partial Seizures Extension Study

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• met the inclusion/exclusion criteria for A0081005

• have completed the 21-week study and have shown a significant clinical response and wish to continue treatment

Exclusion Criteria:

• Having a treatable cause of seizure.

• Having a progressive neurological or systemic disorder